EICHOR
● Not Yet Recruiting
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Condition: Epilepsy · Sponsor: Shanghai UniXell Biotechnology Co., Ltd
About this study
This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary efficacy of UX-GIP001. This is an open-label, single-arm study. All enrolled participants will receive the active investigational cell therapy. Seizure frequency and safety parameters will be evaluated by comparing post-transplant outcomes to pre-transplant baselines.
This description comes directly from the study's public registry record.
Talk to the study team
Xianwei Zhi · +86-21-60197620 · xianweizhi@unixell.com
Always discuss trial participation with your own doctor first.
Locations (3)
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | — |
| West China School of Medicine and West China Hospital, Sichuan University | Chengdu, Sichuan, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07572812